DTP-poliovirus vaccine - Mitsubishi Tanabe Pharma

Drug Profile

DTP-poliovirus vaccine - Mitsubishi Tanabe Pharma

Alternative Names: BK-4SP; Diphtheria-toxoid tetanus-toxoid pertussis-PT-FHA-inactivated poliovirus combined vaccine; Tetrabik

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Research Foundation for Microbial Diseases of Osaka University
  • Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 26 Oct 2012 Launched for Diphtheria in Japan (SC)
  • 26 Oct 2012 Launched for Pertussis in Japan (SC)
  • 26 Oct 2012 Launched for Poliomyelitis in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top